La vendita allo scoperto per LCI Industries dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di LCI Industries. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

LCI Industries (NYSE:LCII) Azioni, Report sulle vendite allo scoperto

LCI Indus

LCI Industries Inc supplies domestically and internationally components for the original equipment manufacturers of recreational vehicles and adjacent industries including buses; and trailers used to haul boats, livestock, equipment, and other cargo. It has two reportable segments; the original equipment manufacturers segment and the aftermarket segment. The OEM Segment manufactures or distributes components for the OEMs of RVs and adjacent industries, including buses; trailers used to haul boats, livestock, equipment, and other cargo; trucks; pontoon boats; trains; manufactured homes; and modular housing. Its products are sold to manufacturers of RVs such as Thor Industries, Forest River, Winnebago, and other RV OEMs, and to manufacturers in adjacent industries.

LCI Industries

LCI Industries Inc

IBM's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) stock is strutting like it owns the runway. Up 48% in the past year and 13% just this year, the legacy tech giant is flexing serious momentum and the charts are confirming it.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0507"><img loading="lazy" decoding="async" width="633" height="488" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07082641/Screenshot-2025-05-07-at-5.56.20-PM.png" alt="" class="wp-image-905522" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07082641/Screenshot-2025-05-07-at-5.56.20-PM.png 633w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07082641/Screenshot-2025-05-07-at-5.56.20-PM-300x231.png 300w" sizes="(max-width: 633px) 100vw, 633px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0507">Chart created using Benzinga Pro</a>
Trading at $249.12, IBM stock sits comfortably above its five, 20 and 50-day moving averages, with a bullish MACD (moving average convergence/divergence) and RSI (relative strength index) suggesting there's still gas in the tank. Technical traders call it &#8216;strongly bullish.&#8217; Bulls call it a &#8220;no-brainer."
But IBM isn't just riding the AI wave &#8211; it's building the surfboard. At the IBM Think conference in Boston, analysts came away impressed with the company's laser-focused AI and hybrid cloud strategy. 
Read Also: <a href="https://www.benzinga.com/25/05/45218573/ibms-ai-watsonx-integrates-with-oracle-cloud-to-boost-enterprise-productivity">IBM AI Watsonx Integrates With Oracle Cloud To Boost Enterprise Productivity</a>
<h2 class="wp-block-heading">Why Dan Ives Is &#8216;Incrementally More Bullish&#8217; On IBM</h2>
Wedbush's Dan Ives is going full throttle, reiterating an Outperform rating and setting a $300 price target. He left the event "incrementally more bullish," noting IBM's sprawling AI use cases, including 70+ AI-infused workflows and over $5B already tied to its generative AI business.
The Z17 mainframe is back in the spotlight, Watsonx Orchestrate lets users build AI agents in minutes, and management is even cozying up with Meta to potentially integrate into the Llama LLM stack. As Ives puts it, IBM's stack is "built for the enterprise AI revolution."
<h2 class="wp-block-heading">JPMorgan Says IBM Is Leading By Example</h2>
JPMorgan's Brian Essex is more measured, holding a Neutral rating, but even he admits IBM is leading by example. He highlighted IBM's internal AI efforts, which have saved $3.5 billion, automating everything from HR to financial forecasting, and proving it&#8217;s not just selling AI—it's living it.
With HashiCorp integration unlocking hybrid automation and a bet on small models paying off, IBM seems determined to reinvent enterprise tech one AI agent at a time.
IBM isn't your grandfather's tech stock anymore. It's leaner, smarter and increasingly essential in the AI-powered future of enterprise.
Don't be surprised if $300 is just the next pit stop.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/05/45251508/warren-buffett-falls-behind-nancy-pelosi-in-stock-market-returns-over-the-last-11-years-heres-what-data-shows">Warren Buffett Falls Behind Nancy Pelosi In Stock Market Returns Over The Last 11 Years: Here&#8217;s What Data Shows</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

Technicals

Analyst Ratings

Tech

Trading Ideas

IBM Thinks Big, AI Delivers Bigger – Why Bulls Are Charging Toward $300

Keybanc analyst Todd Thomas maintains Getty Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTY#NYSE">GTY</a>) with a Overweight and lowers the price target from $35 to $33.

News

Price Target

Keybanc Maintains Overweight on Getty Realty, Lowers Price Target to $33

BWS Financial analyst Hamed Khorsand maintains Interparfums (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPAR#NASDAQ">IPAR</a>) with a Buy and maintains $172 price target.

IPAR

BWS Financial Maintains Buy on Interparfums, Maintains $172 Price Target

WIIM

HGTY

Hagerty shares are trading higher after the company reported better-than-expected Q1 financial results.

Keybanc analyst Alex Markgraff maintains Global Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) with a Overweight and raises the price target from $80 to $90.

Keybanc Maintains Overweight on Global Payments, Raises Price Target to $90

RCUS

Arcus Biosciences shares are trading lower after the company reported worse-than-expected Q1 sales results. Also, Wells Fargo lowered its price target on the stock from $29 to $26.

PARR

Par Pacific Holdings shares are trading higher after the company reported better-than-expected Q1 sales results.

GEO Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) shares are trading lower after the company reported first-quarter revenue of $604.6 million, which missed <a href="https://www.benzinga.com/pressreleases/25/05/b45246791/the-geo-group-reports-first-quarter-2025-results" target="_blank" rel="noreferrer noopener">the consensus of $611.81 million</a>.
<ul>
<li>Adjusted EBITDA declined to&nbsp;$99.8 million&nbsp;from&nbsp;$117.6 million&nbsp;a year ago quarter.</li>
<li>Adjusted EPS&nbsp;of&nbsp;14 cents came below&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">the consensus of&nbsp;18 cents</a>.</li>
<li>The results reflect a general and administrative expense increase of around $5 million.</li>
<li>At the end of the first quarter, net debt totaled approximately $1.68 billion, with around $65 million in cash and cash equivalents.</li>
</ul>
George C. Zoley, Executive Chairman of GEO, said, &#8220;During the first quarter of 2025, we announced two important contract awards for the reactivation of two company-owned facilities totaling 2,800 beds and representing in excess of $130 million in annualized revenues.&#8221;
&#8221;We have taken several important steps to be prepared to meet that opportunity, including making a significant investment commitment of $70 million to strengthen our capabilities to deliver expanded detention capacity, secure transportation, and electronic monitoring services to ICE and the federal government. We also recently completed a reorganization of our senior management team to oversee the operational execution of this expected future growth activity.&#8221;
Outlook: Geo raised FY25 outlook for EPS to 77 cents to 89 cents from 74 cents to 88 cents (vs. the consensus estimate of $1.22) and revenue to around $2.53 billion from $2.50 billion <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">(vs. consensus of $2.66 billion)</a>.
For the second quarter, the company expects second quarter GAAP EPS of 15 cents to 17 cents vs. the street view of 24 cents and sales of $615 million—$625 million vs. the consensus of $635.62 million.
In 2025, the company expects to further reduce the total net debt by around&nbsp;$150 million&nbsp;to&nbsp;$175 million, bringing the total net debt to about&nbsp;$1.54 billion.
For 2025, the company projects capital expenditures of $120 million-$135 million.
&#8220;The first half of the year is expected to be impacted by higher overhead and operating expenses as well as increased capital expenditures to position our company for future growth, which is expected to begin to layer in during the second half of 2025 and normalize in 2026.&#8221;, added Zoley.
Investors can gain exposure to the stock via&nbsp;Ballast Small/Mid Cap ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGMT#NYSE">MGMT</a>) and&nbsp;Innovator IBD Breakout Opportunities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOUT#NYSE">BOUT</a>).
Price Action: GEO shares are down 3.16% at $30.37 at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/legal/25/05/45226604/president-trump-wants-to-reopen-alcatraz-heres-what-it-would-take" target="_blank" rel="noreferrer noopener">President Trump Wants To Reopen Alcatraz: Here&#8217;s What It Would Take</a></li>
</ul>
Image: Shutterstock

Earnings

Equities

Mid Cap

Guidance

Movers

BOUT

MGMT

GEO Missed Q1 Targets On Rising Costs And Debt, Guides Q2 Below Street Estimates

Keybanc analyst Jeffrey Hammond maintains Celanese (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) with a Overweight and raises the price target from $71 to $76.

Keybanc Maintains Overweight on Celanese, Raises Price Target to $76

Barrington Research analyst Vincent Colicchio maintains Hackett Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCKT#NASDAQ">HCKT</a>) with a Outperform and lowers the price target from $36 to $32.

HCKT

Barrington Research Maintains Outperform on Hackett Group, Lowers Price Target to $32

IMPORTANT SAFETY INFORMATION ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).
Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.
The most common adverse reactions (≥1%) for ZORYVE cream 0.3% for plaque psoriasis include diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).
The most common adverse reactions (≥1%) for ZORYVE cream 0.15% for atopic dermatitis include headache (2.9%), nausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%).
The most common adverse reactions (≥1%) for ZORYVE foam 0.3% for seborrheic dermatitis include nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).

Biotech

General

ARQT

Arcutis Biotherapeutics Says ZORYVE Foam 0.3% Linked To Adverse Reactions Including Headache, Nausea, And Diarrhea, With Flammability Risk And Contraindications For Liver-Impaired Patients Highlighted In Safety Profile Under FDA Review

RVLV

Revolve Group shares are trading lower after the company reported worse-than-expected Q1 sales results. Also, Raymond James and UBS lowered their respective price targets on the stock.

Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 20 years by 6.64% on an annualized basis producing an average annual return of 14.78%. Currently, Marsh &amp; McLennan Cos has a market capitalization of $111.92 billion. 
Buying $1000 In MMC: If an investor had bought $1000 of MMC stock 20 years ago, it would be worth $15,844.79 today based on a price of $227.13 for MMC at the time of writing.
<h3>Marsh &amp; McLennan Cos's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746631889_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Marsh & McLennan Cos 20 Years Ago Would Be Worth Today

Vishay Intertechnology shares are trading lower after the company reported worse-than-expected Q1 sales results.

DVAX

Dynavax Technologies shares are trading lower after the company reported worse-than-expected Q1 financial results.

Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) is set to report its first-quarter financial results after Wednesday's closing bell. Here's a look at what to <a href="https://www.benzinga.com/general/sports/25/05/45180070/kentucky-derby-2025-how-to-watch-betting-odds-and-horses-backed-by-dutch-bros-founder-john-malone-george-soros">expect in the print. </a>
What To Watch: Wall Street will be watching to see if the drive-thru coffee chain can maintain the remarkable growth reported in previous quarters.
Analysts expect Dutch Bros to deliver revenue of approximately $344 million, reflecting 25% year-over-year growth, which is a slowdown compared to the 39.5% growth seen in the same quarter last year.&nbsp;
Read Next: <a href="https://www.benzinga.com/news/legal/25/05/45226604/president-trump-wants-to-reopen-alcatraz-heres-what-it-would-take?utm_source=articleShare">President Trump Wants To Reopen Alcatraz: Here&#8217;s What It Would Take</a>
However, foot-traffic <a href="https://www.placer.ai/anchor/articles/dutch-bros-gains-but-starbucks-holds-top-spot">data from </a>Placer.ai shows Dutch Bros' first-quarter visits were up 13.4% year-over-year, which could point to the potential for significant revenue increases. 
Company executives <a href="https://www.benzinga.com/25/02/43676849/dutch-bros-stock-rallies-after-blockbuster-q4-results-details">previously guided </a>fiscal 2025 revenue to be between $1.55 billion and $1.57 billion, which could also indicate a large beat of the consensus revenue estimate. 
Expert Ideas: Dutch Bros stock has a consensus price target of $70.06 based on the ratings of 18 analysts, according to <a href="https://www.benzinga.com/quote/BROS/analyst-ratings">data from</a> Benzinga Edge. Wedbush issued a high of $90 on March 31, representing a 48% potential upside from current levels. 
Analysts expect the company to report quarterly earnings of 11 cents per share on revenue of $344.67 million. Dutch Bros has beaten top and bottom-line consensus estimates in each of the last six quarters. 
Dutch Bros stock has had volatile reactions to earnings releases in the past, with the stock price jumping more than 25% in after-hours trading following the company's fourth-quarter release.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/05/45239803/sarepta-therapeutics-stock-plummets-after-q1-results-heres-why?utm_source=articleShare">Sarepta Therapeutics Stock Plummets After Q1 Results: Here&#8217;s Why&nbsp;</a></li>
</ul>
Photo: Shutterstock

Previews

Restaurants

BROS

Dutch Bros Q1 Earnings Preview: Will 13% Foot-Traffic Growth Lead To Another Blockbuster Quarter?

Keybanc analyst Jeffrey Hammond maintains Atkore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) with a Overweight and raises the price target from $70 to $80.

ATKR

Keybanc Maintains Overweight on Atkore, Raises Price Target to $80

TRIP

TripAdvisor shares are trading higher after the company reported better-than-expected Q1 financial results.

Barrington Research analyst Kevin Steinke maintains Distribution Solns Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGR#NASDAQ">DSGR</a>) with a Outperform and lowers the price target from $44 to $39.

DSGR

Barrington Research Maintains Outperform on Distribution Solns Gr, Lowers Price Target to $39

Chemours shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results. Also, UBS lowered its price target on the stock from $18 to $17.

Press Releases

LCI Industries Fourth Quarter and Full Year 2024 Conference Call Scheduled for February 11, 2025, at 8:30 a.m. ET

LCI Industries Reports Fourth Quarter and Full Year Financial Results

LCI Industries Declares Quarterly Cash Dividend

LCI Industries to Participate in Upcoming Raymond James Conference

LCI Industries Announces Proposed Offering of $400 Million Aggregate Principal Amount of Convertible Senior Notes and Proposed Refinance of Term Loan

LCI Industries Announces Pricing of Offering of $400 Million Aggregate Principal Amount of 3.00% Convertible Senior Notes

LCI Industries to Participate in Upcoming Roth Capital Partners Conference

LCI Industries First Quarter 2025 Conference Call Scheduled for May 6, 2025, at 8:30 a.m. ET

Lippert Acquires Freedman Seating Company

LCI Industries Reports First Quarter Financial Results

LCII

Adient

Autoliv

American Axle & Manufacturing Holdings, Inc. Common Stock

American Axle & Mfg Hldgs

BorgWarner

Cooper-Standard Holdings Inc. Common Stock

Cooper-Standard Holdings

Dana

Dorman Products

ECARX Holdings Inc. - Class A Ordinary shares

ECARX Holdings

Fox Factory Holding

Gentex

Garrett Motion

Holley

Hesai Group - American Depositary Share, each ADS represents one Class B ordinary share

Comments

LCI Industries

Vendite allo scoperto

LCI Industries (NYSE:LCII) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO